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Summary
BACKGROUND: Patients with acute coronary syndrome
(ACS) transferred to regional nonacademic hospitals after
percutaneous coronary intervention (PCI) may receive few-
er preventive interventions than patients who remain in
university hospitals. We aimed at comparing hospitals with
and without PCI facilities regarding guidelines-recommen-
ded secondary prevention interventions after an ACS.
METHODS: We studied patients with ACS admitted to a
university hospital with PCI facilities in Switzerland, and
either transferred within 48 hours to regional nonacademic
hospitals without PCI facilities or directly discharged from
the university hospital. We measured prescription rates of
evidence-based recommended therapies after ACS includ-
ing reasons for nonprescription of aspirin, statins, β-block-
ers, angiotensin converting-enzyme inhibitors (ACEI) / an-
giotensin II receptor blockers (ARB), along with cardiac
rehabilitation attendance and delivery of a smoking cessa-
tion intervention.
RESULTS: Overall, 720 patients with ACS were enrolled;
541 (75.1%) were discharged from the hospital with PCI
facilities, 179 (24.9%) were transferred to hospitals without
PCI facilities. Concomitant prescription of aspirin, β-
blockers, ACEI/ARB and statins at discharge was similar
in hospitals with and without PCI facilities, reaching 83.9%
and 85.5%, respectively (p = 0.62). Attendance at cardiac
rehabilitation reached 55.5% for the hospital with PCI fa-
cilities and 65.7% for hospitals without PCI facilities (p =
0.02). In-hospital smoking cessation interventions were de-
livered to 70.8% patients exclusively at the hospital with
PCI facilities.
CONCLUSION: Quality of care for patients with ACS dis-
charged from hospitals without PCI facilities was simil-
ar to that of patients directly discharged from the hospital
with PCI facilities, except for in-hospital smoking cessa-
tion counselling and cardiac rehabilitation attendance.
Key words: acute coronary syndrome; quality of care;
clinical guidelines; percutaneous coronary intervention;
secondary prevention; cardiac rehabilitation
Introduction
Compared with university hospitals, smaller regional non-
academic hospitals might be prone to low quality of care,
particularly regarding appropriate treatment prescribed at
discharge [1]. Clinical guidelines for best-practice man-
agement of acute coronary syndrome (ACS) recommend
the prescription of antiplatelet drugs, statins, angiotensin
converting enzyme inhibitors (ACEI) and β-blockers, as
well as in-hospital smoking cessation interventions and the
organisation of cardiac rehabilitation at discharge [2–5].
Using these guidelines as reference for quality of care, sub-
optimal management has often been reported with import-
ant geographic variation both in the USA and in Europe
[6–10]. To explain these geographic variations, studies
have highlighted the role of the size and type of hospitals,
academic vs nonacademic, or the presence of percutaneous
coronary intervention (PCI) facilities [11, 12].
Taking into account reasons for nonprescription, we pre-
viously reported quality of care at discharge for patients
with ACS in four university hospitals in Switzerland [13].
However, many patients with ACS initially treated in uni-
versity hospitals with PCI facilities are rapidly transferred
to regional nonacademic hospitals without PCI facilities,
and very few data exist about the quality of care for patients
discharged from these smaller hospitals. We aimed to as-
sess the prescription rate of recommended preventive drugs
and interventions after ACS, including reasons for nonpre-
scription, comparing a large university hospital with PCI
facilities with regional nonacademic hospitals without PCI
facilities in Switzerland.
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Methods
Study population
Patients were recruited in a university hospital with PCI
facilities, which takes care of patients with ACS from a
large part of the French-speaking region of Switzerland.
Between September 2009 and March 2013, patients with
an ACS who underwent angiography were enrolled. Pa-
tients were part of the large SPUM-ACS cohort study (Spe-
cial Program University Medicine – Acute Coronary Syn-
drome) designed to assess long-term prognosis and quality
of care after ACS in Switzerland [13, 14]. After admission
and initial treatment in the main university hospital, pa-
tients living in peripheral geographic areas were transferred
within 24–48 hours after PCI to regional nonacademic hos-
pitals without PCI facilities. For each participant, medical
records were abstracted, including the discharge letter,
laboratory results and all medical procedures, by both
trained study nurses and a medical doctor. ACS was
defined as presence of symptoms analogous to angina pec-
toris (dyspnoea, chest pain) accompanied by one of the fol-
lowings parameters: ST-segment elevation or depression,
T inversion or dynamic electrocardiogram modifications,
evidence of positive troponin and known coronary heart
disease (status after myocardial infarction, bypass surgery
or percutaneous transluminal coronary angioplasty), and
confirmed on the angiography (International Classification
of Disease, 10th Revision [ICD-10] codes I20.0,
I21.0–I21.9, and I22.0–I22.9). The study protocol was ap-
proved by the local institutional review board and all parti-
cipants provided written informed consent.
Outcome measures
Prescription rates of recommended secondary prevention
medication at discharge were assessed for aspirin, P2Y12
inhibitors (clopidogrel, prasugrel or ticagrelor), statins, β-
blockers, and ACEI or angiotensin II receptor blockers
(ARB), based on the European Society of Cardiology
(ESC) guidelines 2008 and the American College of Cardi-
ology/American Heart Association (ACC/AHA) 2008 per-
formance measures for adults with ST-segment elevation or
non-ST-segment elevation myocardial infarction (STEMI/
NSTEMI) (supplementary table S1 in appendix) [13]. We
included the following prespecified reasons for nonpre-
scription [15] of aspirin: “active bleeding during hospital
stay”, “coumadin/warfarin prescribed at discharge” and
“aspirin allergy”. For ACEI/ARB reasons for nonprescrip-
tion were: “moderate or severe aortic stenosis” and “ACEI
and/or ARB allergy”; for β-blockers reasons were: “β-
blocker allergy” and “second- or third-degree atri-
oventricular heart block”. For β-blockers, we also included
the reason “bradycardia (heart rate <60/min) on day of
discharge” given its high reported frequency [15]. For all
medications, we included the reason “other reason docu-
mented by physician” and “patient refusal”. Additionally,
for patients transferred to hospitals without PCI facilities
after angiography, we further examined the medication pre-
scribed at time of transfer. Performed cardiac rehabilitation
rates were assessed from a combination of discharge med-
ical records and self-reported information at the 1-year
follow-up visit. If participants were not offered cardiac re-
habilitation at discharge from the hospital, but reported
having had cardiac rehabilitation at 1-year follow-up, they
were considered as having performed cardiac rehabilita-
tion. Participants directly discharged to cardiac rehabilita-
tion from the hospital but not reporting having had cardi-
ac rehabilitation at the 1-year follow-up were considered
as having performed cardiac rehabilitation. Participants for
whom the cardiac rehabilitation was planned at discharge
but not reporting having had cardiac rehabilitation at 1 year
were considered as having not performed cardiac rehabil-
itation. In-hospital smoking cessation counselling was ab-
stracted from the discharge letter for the hospital stay. At
the university hospital with PCI facilities, this interven-
tion was performed by a medical doctor trained in motiv-
ational interviewing, and ranged from a brief intervention
to a complete motivational intervention with enhancement
of nicotine replacement therapy, according to the patient’s
willingness to quit.
Covariates
Patients’ health characteristics, including history of dia-
betes, hypertension, dyslipidaemia, heart failure, stroke,
angina pectoris, myocardial infarction, previous cardiac in-
tervention such as PCI or coronary artery bypass graft, and
renal insufficiency requiring dialysis were self-reported or
abstracted from available medical documents, such as files
from the emergency department, or from the general practi-
tioner. Body mass index was defined as the weight divided
by height squared and based on self-reported weight and
height. Smoking status was categorised into active, former
and never-smokers. Former smokers were those who had
smoked at least one cigarette a day during at least 1 year,
and were nonsmokers for more than 1 month before inclu-
sion.
Statistical analysis
Prescription rates of recommended therapies were reported
independently for each drug, as well as after grouping the
concomitant use of aspirin, β-blockers, ACEI or ARB, and
statins into one variable. The quality of the data was strong
with few missing data (<5%), equally distributed among
both groups according to presence of PCI facilities, except
for the variable left ventricular ejection fraction (LVEF).
Available data only were analysed. Bivariate analyses were
performed using χ2 tests and Fischer’s exact test to compare
frequencies between patients discharged from hospitals
with and without PCI facilities. All p-values <0.05 were
considered statistically significant. Analyses were per-
formed using Stata version 13 (StataCorp, College Station,
Texas, USA).
Results
Out of the 720 patients with ACS who underwent angio-
graphy and were enrolled in the study, 541 (75.1%) were
discharged home directly from the university hospital, and
179 (24.9%) were transferred after PCI to regional non-
academic hospitals without PCI facilities. The mean age
of patients with ACS was 63.4 (standard deviation [SD]
12.6) years, 77.5% were men, 57.2% had hypertension,
20.0% had pre-existing diabetes and 39.0% were active
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smokers. Participants discharged from the university hos-
pital with PCI facilities were more likely to have dyslip-
idaemia, hypertension, diabetes, and non-ST-segment el-
evation myocardial infarction (NSTEMI) than those dis-
charged at regional nonacademic hospitals without PCI fa-
cilities (table 1).
Taking into account reasons for nonprescription, the pre-
scription rate of evidence-based therapies at discharge, in-
cluding statins, aspirin, β-blockers, ACEIs or ARBs was
similar between the university hospital with PCI facilities
and the regional nonacademic hospitals without PCI facil-
ities (83.9 vs 85.5%, p = 0.6) (fig. 1 and table 2). Reasons
for not prescribing medication reached 10.1% for β-block-
ers and 3.6% for ACEI/ARB and are reported in details by
drug categories in supplementary table S2 (appendix). Ex-
cept for one patient, all were discharged with antiplatelet
agents, including aspirin and P2Y12 inhibitors for parti-
cipants with stent implantation, independently of the type
of hospital. There was no difference in adherence to drugs
when data were stratified according to gender (data not
shown). Overall, attendance at cardiac rehabilitation was
better in the regional nonacademic hospitals without PCI
capability as compared with the university hospital (55.5
vs 65.7%, p = 0.02). Two-thirds of smokers with ACS had
in-hospital smoking cessation interventions when hospital-
ised in the university hospital with PCI facilities, where-
as smokers transferred to regional nonacademic hospitals
without PCI facilities did not benefit from smoking ces-
sation interventions in the secondary hospitals, but half of
them had a first approach in the university hospital with
PCI facilities (table 3).
The prescription rates of β-blockers and ACEI or ARB at
time of transfer to regional non-academic hospitals without
PCI facilities were 83.8% and 77.7%, respectively, and in-
creased to 93.3% for both (p <0.001) at discharge (table 3).
Discussion
We found that rates of evidence-based drug prescription at
discharge for patients with ACS hospitalised in a university
hospital with PCI facilities and then transferred to a region-
al nonacademic hospital without PCI facilities were simil-
ar to the prescription rates for patients directly discharged
from the university hospital. However, in-hospital smoking
cessation interventions were exclusively performed at the
university hospital with PCI capability, and cardiac rehab-
ilitation was more frequent in patients discharged from re-
gional nonacademic hospitals without PCI facilities.
In Switzerland, quality of care at discharge for patients
with ACS has been mostly documented for university hos-
pitals or hospitals with PCI facilities [13, 16]. A recent
study, based on a prospective Swiss national registry
named AMIS Plus [17], of patients with ACS in 76 hospit-
als found no difference in 1-year mortality after ACS ac-
Table 1: Baseline characteristics of patients with acute coronary syndrome, according to type of hospital from which they were discharged (n = 720).
Hospital with PCI facilities
n = 541
Hospital without PCI facilities
n = 179
p-value
Age, y 64.0 ± 12.8 61.9 ± 11.9 0.053
Men, n (%) 421 (78.2) 137 (76.5) 0.722
BMI (kg/m2) ± SD 27.1 ± 4.4 26.7 ± 4.1 0.271
Education level, n (%) (n = 718) * 0.297
Apprenticeship or lower 366 (67.9) 129 (72.1)
High school or university graduation 173 (32.1) 50 (27.9)
History of dyslipidaemia, n (%) 388 (71.7) 103 (57.5) <0.001
History of hypertension, n (%) 322 (59.5) 90 (50.3) 0.030
History of diabetes, n (%) 118 (21.8) 26 (14.5) 0.035
Smoking status, n (%) 0.180
Active 202 (37.3) 79 (44.1)
Former 174 (32.2) 51 (28.5)
Never 165 (30.5) 49 (27.4)
Pre-existing coronary artery disease, n (%) † 151 (27.9) 33 (18.4) 0.012
History of CHF, n (%) 18 (3.3) 5 (2.8) 0.725
Renal insufficiency requiring dialysis, n (%) 6 (1.1) 2 (1.1) 0.993
ACS diagnosis, n (%) 0.003
STEMI 243 (44.9) 104 (58.1)
NSTEMI 252 (46.6) 69 (38.5)
Unstable angina 46 (8.5) 6 (3.4)
Revascularisation treatment, n (%) 0.025
PCI and stenting 392 (72.3) 150 (83.8)
PCI no stenting 40 (7.4) 10 (5.6)
CABG 36 (6.7) 2 (1.1)
Conservative 73 (13.5) 17 (9.5)
ACS = acute coronary syndrome; BMI = body mass index; CABG = coronary artery bypass graft; CHF = chronic heart failure; NSTEMI = non-ST-elevation myocardial
infarction; PCI = percutaneous coronary intervention; SD = standard deviation; STEMI = ST-elevation myocardial infarction; SD = Standard deviation
* Education level: variable based on 718 patients.
† Variable including history of myocardial infarction, PCI and CABG.
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cording to the size of hospital [18]. However, this study
was based on administrative data, and reasons for nonpre-
scription and in-hospital smoking cessation interventions
were not collected. By contrast, hospitals with full inter-
ventional capabilities in the USA were associated with bet-
ter prescription of recommended drugs compared with hos-
pital without PCI facilities [12]. In France, hospitals with
PCI facilities when compared with those without PCI facil-
ities have also been associated with higher drug prescrip-
tion rates at discharge [19]. In our study, rates of drugs pre-
scription did not differ between hospitals with or without
PCI facilities and thus provide reassuring confirmation re-
garding safety and quality of care for patients with ACS
discharged from smaller regional nonacademic hospitals
not equipped with highly specialised devices. However the
comparison of drug prescription rates between our study
and others from Europe or the USA is limited by the differ-
ent organisation of healthcare systems. In Switzerland, hos-
pitals are grouped into geographical healthcare networks,
and patients requiring PCI are transferred from hospitals
without PCI facilities to the main hospital, able to provide
highly specialised care. During the last decade, various
quality improvement strategies have been implemented in
Switzerland [20], which might also explain the improve-
ment witnessed in quality of care for ACS patients [13].
We found that in regional nonacademic hospitals without
PCI facilities, smokers with ACS were discharged without
any in-hospital antismoking intervention. This is in contrast
with current international guidelines, which consider early
counselling for smoking cessation after ACS as a top pri-
ority [2–5]. Despite the proven efficacy to reduce mortality
[21], underuse of in-hospital smoking cessation interven-
tions is globally reported [22]. This gap in quality of care is
probably due to a lack of resources and trained staff avail-
able in smaller regional nonacademic hospitals. During the
study period at the university hospital with PCI facilit-
ies, there was an “on-call” service for smoking cessation,
meaning that smoking intervention was used when patients
or the medical staff asked for it. Thus, to reduce the gap in
quality of care between hospitals with and without PCI fa-
Table 2: Prescription rates of secondary prevention therapies at discharge, according to type of hospital (n = 720).
Hospital with PCI facilities
n = 541
n (%)
Hospital without PCI facilities
n = 179
n (%)
p-value
Concomitant use of aspirin, β-blockers, ACEI or ARB, and statins 454 (83.9) 153 (85.5) 0.620
Aspirin 540 (99.8) 179 (100.0) 0.565
P2Y12 inhibitors (n = 542) * 392 (100.0) 150 (100.0) 1.000
β-blockers 502 (92.8) 167 (93.3) 0.819
ACEI/ARB † 483 (89.3) 167 (93.3) 0.116
LVEF ≥40% (n = 564) 404 (88.6) 99 (91.7) 0.356
LVEF <40% (n = 58) 44 (95.7) 12 (100.0) 0.462
Statins 532 (98.3) 176 (98.3) 0.991
Performed cardiac rehabilitation ‡ 281 (55.5) 113 (65.7) 0.020
Performed home-based cardiac rehabilitation 90 (16.6) 37 (20.7) 0.220
Smoking intervention for smokers (n = 281) 143 (70.8) 0 (0.0) NA
Nitrates ¶ 84 (15.5) 27 (15.1) 0.887
ACEI = angiotensin converting-enzyme inhibitors; ARB = angiotensin II receptor blockers; LVEF = left-ventricular ejection fraction; PCI = percutaneous coronary
intervention
* Prescription of P2Y12 inhibitors according to participants treated with PCI+stent (n = 542).
† LVEF measurement was missing for 98 patients, 39 in patients discharged from hospital with PCI facilities vs 59 in those discharge from hospital without PCI facilities.
‡ There were 42 missing values, equally distributed among both types of hospitals (6.5% vs 3.9%).
¶ Including slow release and on demand nitrates.
Table 3: Prescription rate of secondary prevention therapies at time of transfer to hospital without PCI facilities and at final discharge (n = 179).
At transfer to hospital without PCI
facilities
n = 179
n (%)
At discharge from hospital without
PCI facilities
n = 179
n (%)
p- value
Concomitant use of aspirin, β-blockers, ACEI or ARB, and statins 111 (62.0) 153 (85.5) <0.001
Aspirin 179 (100.0) 179 (100.0) 1.000
P2Y12 inhibitors (n = 150) * 150 (100.0) 150 (100.0) 1.000
β-blockers 150 (83.8) 167 (93.3) <0.001
ACEI/ARB 139 (77.7) 167 (93.3) <0.001
LVEF ≥40% (n = 108) 84 (77.8) 99 (91.7) <0.001
LVEF <40% (n = 12) 11 (91.7) 12 (100.0) 0.307
Statins 171 (95.5) 176 (98.3) 0.126
Performed cardiac rehabilitation NA 113 (65.7) NA
Smoking intervention 38 (48.1) 0 (0.0) NA
Nitrates † 15 (8.4) 27 (15.1) <0.001
ACEI = angiotensin converting-enzyme inhibitors; ARB = angiotensin II receptor blockers; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary
intervention
* Prescription of P2Y12 inhibitors according to participants treated by PCI + stent (n = 150).
† Including slow release and on demand prescribed nitrates.
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cilities in Switzerland, implementing in-hospital smoking
cessation counselling in all type of hospitals is necessary,
ideally by adopting a systematic intervention for smokers
with organised follow-up after discharge [21]. A step has
already been taking with a national programme promoting
smoking cessation interventions and offering hospital sup-
port [23].
Regarding cardiac rehabilitation, our rates of attendance
were very high in comparison with current literature [7,
24]. Almost two-thirds of our patients were enrolled in a
cardiac rehabilitation programme, with a higher rate ob-
served at hospitals without PCI facilities. Lower education
level, older age (>65 years), and pre-existing cardiac dis-
eases or cardiovascular risk factors are commonly reported
as being negatively associated with cardiac rehabilitation
performance [25], despite its proven efficacy to reduce the
risk of recurrence and mortality [25]. Overall, our rates at-
test a good implementation of cardiac rehabilitation in ACS
management in Switzerland, particularly in regional non-
academic hospitals without PCI facilities.
Our study has several limitations. First, our studied popu-
lation derived from only one university hospital and might
not reflect standard care for the entire Swiss population.
However, our study sample was derived not from a ran-
domized controlled trial but from an observational study
without specific exclusion criteria, as reflected by our bal-
anced proportions of STEMI, NSTEMI and unstable
angina, which increases the generalisability of the findings.
Second, we did not assess clinical outcome data after hos-
pital discharge to assess quality of care, and further studies
should examine this issue. The aim of this study was not
to report on the quality of care for all patients in Switzer-
land, but to determine whether adherence to recommended
a
b
Figure 1
Secondary prevention therapies and interventions with documented
contraindications according to presence of PCI facilities. (a)
Hospital with PCI facilities. (b) Hospitals without PCI facilities.
ACEI = angiotensin converting-enzyme inhibitors; ARB =
angiotensin II receptor blockers; Bblockers = β-blockers; PCI =
percutaneous coronary intervention
secondary prevention interventions was high for patients
transferred to hospital without PCI facilities after undergo-
ing angiography.
Conclusion
Taking into account reasons for nonprescription, prescrip-
tion rates of recommended secondary prevention drugs
were similar for patients with ACS discharged from uni-
versity hospital with PCI facilities or regional nonacademic
hospitals without PCI facilities, cardiac rehabilitation at-
tendance was slightly better for patients discharged from
hospitals without PCI facilities. To further improve quality
of care after ACS, efforts should now be oriented toward
the implementation of in-hospital smoking cessation inter-
ventions in smaller regional nonacademic hospitals, where
a major gap in quality of care remains.
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Appendix
Supplementary tables
Table S1: Degree of evidence according to guidelines.
ACC/AHA
STEMI
2009
ACC/AHA
UA/NSTEMI
2007
ESC
STEMI
2008
ESC
NSTEMI
2007
Aspirin IA IA IA IA
Dual antiplatelet therapies IB IB IIaC IA
Β-blockers IA IB IA IA (LVEF <40%)
ACEI/ARB regardless of LVEF IB IIaA IIaA IIaB
ACEI/ARB and LVEF <40% IA IA IA IA
Statins and LDL-cholesterol <2.6 mmol/l IA IA IA IB
Smoking intervention IB IB IB IB
Cardiac rehabilitation IB IB IB –
ACC = American College of Cardiology; ACEI = angiotensin converting enzyme inhibitors; AHA = American Heart Association; ARB = angiotensin II receptor blockers;
ESC = European Society of Cardiology; LDL = low density lipoprotein; LVEF = left ventricular ejection fraction; NSTEMI = non-ST-elevation myocardial infarction; STEMI =
ST-elevation myocardial infarction; UA = unstable angina.
Table S2: Reasons for not prescribing medication or performing cardiovascular preventive interventions.
Hospital with PCI facilities Hospital without PCI facilities
Aspirin
Side effects 1 NA
Allergy 1 NA
Anticoagulation 6 NA
Statin
Side effects 4 1
Allergy 1 0
Refusal 0 0
Other cholesterol-lowering drug 0 1
β-blockers
Side effects 3 0
Haemodynamic compromise 36 21
Atrioventricular blocks 3 0
Delayed prescription 4 2
Not necessary 1 2
ACEI/ARB
Side effects 0 1
Haemodynamic compromise 9 7
Renal failure 3 4
Delayed prescription 0 0
Not necessary 2 0
Cardiac rehabilitation
Rehospitalisation planned 3 0
Insurance problem 1 0
Leave without medical approbation 0 1
Health conditions 2 1
Other re-education 3 0
Not necessary 6 1
Refusal 24 4
Smoking intervention
Ambulatory intervention 2 NA
Already performed recently 1 NA
Refusal 10 NA
ACEI = angiotensin converting-enzyme inhibitors; ARB = angiotensin II receptor blockers; PCI = percutaneous coronary intervention
Side effects includes allergy and intolerance; haemodynamic compromise includes hypotension, bradycardia and right ventricle dysfunction; atrioventricular blocks includes
1st, 2nd, and 3rd degree block
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Figures (large format)
a
b
Figure 1
Secondary prevention therapies and interventions with documented contraindications according to presence of PCI facilities. (a) Hospital with
PCI facilities. (b) Hospitals without PCI facilities.
ACEI = angiotensin converting-enzyme inhibitors; ARB = angiotensin II receptor blockers; Bblockers = β-blockers; PCI = percutaneous coronary
intervention
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